Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy - Related Studies

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

This study has been terminated.

Study NCT00079859. Last updated on June 23, 2005. Information provided by Medical Research Laboratories International

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Familial Hypercholesterolemia

2	Additional conditions recognized in this trial
		Hypercholesterolemia
		Hyperlipoproteinemia Type II

3	More general conditions related to this trial
		Dyslipidemias
		Genetic Diseases, Inborn
		Hyperlipidemias
		Hyperlipoproteinemias
		Lipid Metabolism Disorders
		Lipid Metabolism, Inborn Errors
		Metabolic Diseases
		Metabolism, Inborn Errors

4	Interventions listed in this trial
		Implitapide

5	Sponsors listed in this trial
		Medical Research Laboratories International